30 January 2025
EMA/39003/2025
EMEA/H/C/006165

Public statement

Penbraya (meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed))

Withdrawal of the marketing authorisation in the European Union

On 20 January 2025, the European Commission withdrew the marketing authorisation for Penbraya (meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Pfizer Europe MA EEIG, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Penbraya was granted marketing authorisation in the EU on 14 November 2024 for the "active immunisation of individuals 10 years of age and older to prevent invasive disease caused by *Neisseria meningitidis* groups A, B, C, W, and Y. The use of this vaccine should be in accordance with official recommendations." The marketing authorisation was initially valid for a 5-year period.

The European Public Assessment Report (EPAR) for Penbraya will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union